Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following...
Read More...
Focus:
North-america
-
![FDA withdraws Belviq cancer risk]()
FDA withdraws Eisai’s weight management drug Belviq due to cancer risk
The US Food and Drug Administration (FDA) has requested that Eisai voluntarily withdraw its weight...
Read More...
-
![]()
Codagenix partners Serum Institute of India on Covid-19 vaccine
Biotechnology firm Codagenix has partnered with vaccine manufacturer Serum Institute of India to work together...
Read More...
-
![]()
Preclinical data of Gilead’s remdesivir raises hope for China trials
A study by the US National Institutes of Health (NIH) has demonstrated that Gilead’s antiviral...
Read More...
-
![Covid-19 vaccine]()
Covid-19: Pittsburgh University work on vaccine; Vaxil finds candidate
The University of Pittsburgh, US, has begun efforts to develop a vaccine against the Covid-19...
Read More...
-
![]()
Regeneron’s therapeutic candidate for rare cholesterol disease expected to face pricing pressure
As high drug prices continue to incite public outcry and US legislation, it is nonetheless possible that Regeneron Pharmaceuticals’ drug…
Read More…
-
![]()
Vir Biotechnology discovers two antibodies against new coronavirus
US-based immunology company Vir Biotechnology has identified two monoclonal antibodies (mAbs) that can bind to...
Read More...
-
![CRPC OS Pfizer Astellas]()
Pfizer and Astellas report OS data for Xtandi in non-metastatic CRPC
Japanese company Astellas and US-headquartered Pfizer have announced final overall survival (OS) for Xtandi (enzalutamide)...
Read More...
-
![]()
CDC identifies significant racial disparity among newly diagnosed cases of HIV
The US Centers for Disease Control and Prevention (CDC) recently published nationwide data in the Morbidity and Mortality Weekly Report…
Read More…
-
![ADC unmet need TNBC]()
Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer
Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC...
Read More...
